March 20th 2024
The FDA fast-tracked MVR-T3011, an intratumorally injected oncolytic virus, for treating recurrent or metastatic head and neck squamous cell cancer post-platinum chemotherapy and at least 1 prior anti-PD1/PDL1 therapy.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
CMS Tackles Drug Prices, But What Does This Mean for Patient Care Access?
October 19th 2018Rising prescription drug prices continue to add to the burden of paying for quality healthcare. In an effort to confront such costs, the Centers for Medicare & Medicaid Services has rescinded a prohibition on step therapy for Medicare Advantage plans. But some contend such a policy will reduce patient access to optimal medication.
Read More
Promising Activity Seen With Palbociclib/Cetuximab Combo in HPV-Unrelated HNSCC
July 12th 2018An overall response rate of 39% was induced with the combination of the CDK4/6 inhibitor palbociclib and cetuximab in patients with platinum-resistant, HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma.
Read More
Women With Head and Neck Cancer May Be Severely Undertreated Compared With Men
June 2nd 2018According to study results presented at the 2018 ASCO Annual Meeting, women with head and neck cancer (HNC) are less likely to recieve intensive chemotherapy and radiation when compared with their male counterparts.
Read More
Tracking System Helps Reduce Symptom Severity in Head and Neck Cancers
May 17th 2018In results of a large randomized trial of patients with head and neck cancer who had undergone radiation therapy, patients who used mobile and sensor technology to track their symptoms demonstrated reduced severity of their symptoms compared with patients who received standard care.
Read More